Repligen director Pax Margaret acquires $37,672 in common stock

Published 18/03/2025, 21:00
Repligen director Pax Margaret acquires $37,672 in common stock

In a recent transaction filed with the Securities and Exchange Commission, Pax Margaret, a director at Repligen Corp (NASDAQ:RGEN), purchased 250 shares of the company’s common stock. The shares were acquired at a price of $150.69 each, amounting to a total transaction value of $37,672. Following this acquisition, Margaret now holds 1,043 shares of Repligen directly. The company, currently valued at $8.1 billion, has seen its stock trade between $113.50 and $200.23 over the past 52 weeks. According to InvestingPro data, analysts have set price targets ranging from $155 to $225, suggesting potential upside.

Repligen, a company based in Waltham, Massachusetts, is known for its work in the life sciences sector, specifically in the production of biological products. With annual revenue of $634 million and a strong liquidity position, the company maintains a healthy current ratio of 8.41. While currently not profitable, InvestingPro analysis indicates expected profitability this year, with 12 additional key insights available to subscribers through the comprehensive Pro Research Report.

In other recent news, Repligen Corporation has reported its fourth-quarter and full-year financial results for 2024, with fourth-quarter revenue reaching $167.5 million, a slight increase from the previous year. The full-year revenue amounted to $634.4 million, aligning with H.C. Wainwright’s projections. Looking forward, Repligen’s 2025 revenue guidance is set between $685 million and $710 million, with analysts at H.C. Wainwright forecasting $697.1 million. In a strategic move, Repligen has acquired a bioprocessing desktop portfolio for $70 million, expected to add $10 million in sales for the current year, although it will slightly dilute earnings before interest and taxes. Leerink Partners maintains an Outperform rating with a $200 target, while Canaccord Genuity has increased its price target to $170, maintaining a Hold rating. Evercore ISI has begun coverage on Repligen with an In Line rating and a $155 price target, noting the company’s potential for growth as the market recovers. Repligen’s recent acquisition enhances its upstream capabilities and complements its existing technology portfolio, with MAVEN/MAVERICK and REBEL playing significant roles in its long-term strategy. Despite recent challenges, Repligen’s management anticipates revenue growth of 10%-14% for 2025, excluding COVID-19 impacts, with adjusted earnings per share projected between $1.67 and $1.76.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.